Genetic Testing for Family Members with Suspected Hereditary Cancer Risk
Yes, family members should undergo cascade genetic testing if a pathogenic variant has been identified in the proband (the first affected family member tested), starting with first-degree relatives and using targeted single-site testing for the known familial mutation. 1
Testing Strategy Based on Family Situation
If a Family Member Already Has a Known Pathogenic Variant
- First-degree relatives (parents, siblings, children) should be tested first using targeted single-site testing for the specific familial mutation already identified 2
- This approach is more cost-effective and provides clear yes/no answers about inherited risk
- Approximately 47.5% of invited first-degree relatives complete testing when offered 2
- Testing the affected family member (proband) is always preferred over testing unaffected relatives 3
If No One Has Been Tested Yet
The person with cancer or the strongest clinical features should undergo comprehensive multigene panel testing first 1, 3. This establishes whether a hereditary mutation exists in the family.
For specific cancer types, universal testing is recommended:
- Pancreatic cancer: All patients should undergo genetic testing regardless of age or family history, as typical clinical factors poorly predict mutation carriers 3
- Breast/ovarian cancer: Testing recommended based on personal and family history criteria 3
- Lynch syndrome genes (colorectal/endometrial cancer): Testing based on clinical criteria 3
Which Genes to Test
The specific panel depends on the cancer type in your family:
Breast and Ovarian Cancer
- Core genes: BRCA1, BRCA2, PALB2, ATM, CHEK2 3
Pancreatic Cancer
- BRCA1, BRCA2, CDKN2A, ATM, PALB2, STK11, TP53, Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM) 3
- BRCA2 and CDKN2A are most prevalent (2-6% and 1.5-2.5% respectively) 3
Multiple Cancer Types
- Multigene panels testing 30+ cancer-associated genes may be appropriate 1
Important Considerations and Pitfalls
Timing matters for cancer patients: Test the affected family member near diagnosis if possible, as mortality may limit future testing opportunities, especially with pancreatic cancer 3
Beware of incomplete family testing: In families with variable disease presentation, consider comprehensive panel testing for multiple family members rather than just the proband, as this can identify additional pathogenic variants that single-gene cascade testing would miss 4. Research shows 4.9% of relatives undergoing cascade testing had pathogenic variants in different genes than the known familial mutation 2
Genetic counseling involvement improves outcomes: Families involving genetic counselors have higher cascade testing rates (26.1% vs 21.4%) 5
Disparities to Address
Cascade testing is significantly underutilized, with only 24% of families completing testing 5. Lower rates occur in:
- Male family members (20.6% vs 25% for females) 5
- African American/Black families (16.2%) 5
- Hispanic families (19.7%) 5
- Asian families (20%) 5
- Middle Eastern families (11.6%) 5
Financial barriers are not the primary obstacle - free testing programs do not significantly boost participation 5. Cultural and clinical factors appear more important.